INTRODUCTION {#s1}
============

Candidiasis, a fungal infection caused by yeasts of the genus *Candida*, is the most common oral fungal infection in humans. Among the at least 15 species of *Candida* yeasts that can infect humans, *Candida albicans* is the most prevalent \[[@R1], [@R2]\]. *Candida* species are commensal to healthy humans and are found frequently colonizing the oral mucosa. In addition, they are widespread elsewhere in the human body; however, *Candida* infection (CI) develops in immunocompromised situations due to the great adaptability of these species to different host niches \[[@R3]\]. CI frequently involves the mouth, vagina, glans penis, esophagus, liver, gastrointestinal tract, respiratory tract, and skin. Oral candidiasis is the most common type of fungal infection in the mouth \[[@R4]\] as well as the most common opportunistic oral infection in humans \[[@R5]\]. In Western countries, nearly 75% of adult women are affected by vaginal yeast infections at least once in their lives. Predisposing factors for CI include an impaired immune system and underlying disease states, drugs abuse and prolonged use of antibiotics, decreased digestive secretions, dietary factors, nutrient deficiency, impaired liver function, and altered bowel flora \[[@R6]\].

CI is not an infrequent complication of cancer and cancer-related therapy, and it may also play an active role in cancer development. The relationship between microbial infection and cancer is of great concern. Microbial infection and cancer risk have been investigated for decades, and some types of virus and bacteria are well-known carcinogens \[[@R7]--[@R11]\]. The consideration of candidiasis and certain types of cancer being related to the immunocompromised status of the host \[[@R12]\], scientists have also investigated the possible association between CI and subsequent cancer development, mostly focusing on oral cancers \[[@R13]--[@R15]\]. An earlier nationwide study in Denmark revealed that CI is associated with increases in both short- and long-term risks for several malignancies other than oral cancer \[[@R16]\]. The most recent findings demonstrate that *C. albicans* can promote cancer through several plausible mechanisms \[[@R17]\].

Using nationwide data, we conducted a similar population-based cohort study to evaluate whether CI increases overall and individual cancer risks in Taiwan. In addition, analyses stratified by sex, age, and follow-up time were conducted to determine whether significant findings are more likely to occur in certain groups.

RESULTS {#s2}
=======

The characteristics of the CI and non-CI participants were similar and are listed in Table [1](#T1){ref-type="table"}. The mean (SD) ages of patients in the CI and non-CI cohorts were 39.7 (15.4) and 41.3 (15.0) years, respectively.

###### Baseline characteristics in individuals with and without candida infection

  Characteristics                          Candida infection   p-value       
  ---------------------------------------- ------------------- ------------- -------
  **Age group (year)**                                                       0.99
   20−49                                   27786(79.8)         27771(79.7)   
   50−64                                   3979(11.4)          3988(11.5)    
   ≥ 65                                    3064(8.80)          3070(8.81)    
  **Age, mean ±SD^a^ (year)**              41.3±15.0           39.7±15.4     0.001
  **Sex**                                                                    0.85
   Women                                   31721(91.1)         31707(91.0)   
   Men                                     3108(8.92)          3122(8.96)    
  **Monthly income^b^**                                                      0.96
   \< 15,000                               15697(45.1)         15703(45.1)   
   15,000−19,999                           10381(29.8)         10403(29.9)   
   ≥ 20,000                                8751(25.1)          8718(25.0)    
  **Urbanization level^c^**                                                  0.99
   1 (highest)                             10349(29.7)         10328(29.7)   
   2                                       10927(31.4)         10931(31.4)   
   3                                       6068(17.4)          6077(17.5)    
   4 (lowest)                              7485(21.5)          7493(21.5)    
  **Occupation^d^**                                                          0.95
   Office worker                           18686(53.7)         18724(53.8)   
   Laborer                                 13266(38.1)         13223(38.0)   
   Other                                   2877(8.26)          2882(8.27)    
  **Comorbidity**                                                            
   Chronic obstructive pulmonary disease   4158(11.9)          4188(12.0)    0.73
   Connective tissue disease               450(1.29)           499(1.43)     0.11
   Chronic renal failure                   347(1.00)           380(1.09)     0.22
   Chronic liver failure                   3481(9.99)          3500(10.1)    0.81
   Inflammatory bowel disease              391(1.12)           456(1.31)     0.02
   Diabetes                                1749(5.02)          1718(4.93)    0.59
   Hypertension                            5676(16.3)          5669(16.3)    0.94
   Hyperlipidemia                          4601(13.2)          4562(13.1)    0.66
   HIV infection                           88(0.25)            96(0.28)      0.55
   Coronary artery disease                 3178(9.12)          3196(9.18)    0.81
   Drug dependence                         41(0.12)            49(0.14)      0.40

SD, standard deviation;

Chi-square test;

^a^t-test

^b^Unit: New Taiwan dollar (NTD), 1 NTD is equal to 0.03US dollar;

^c^Urbanization level was categorized according to the population density of the residential area into 4 levels, with Level 1 the most urbanized and Level 4 the least urbanized.

^d^Other occupation category included primarily retired, unemployed, and low-income groups.

The incidence densities, adjusted hazard ratios (AHRs) between the CI and non-CI cohorts and 95% confidence intervals (CIns) are presented in Table [2](#T2){ref-type="table"}. The overall incidence of all cancers was 17% higher in the CI cohort than in the non-CI cohort (3.93 vs. 3.73 per 1000 person-years) with an AHR of 1.19 (95% CIn = 1.09--1.30) in the following 14 years. Compared with the non-CI cohort, patients with CI had a significantly higher risk of hematologic malignancy (AHR=2.20, 95% CIn=1.52--3.18), myeloid leukemia (AHR=2.56, 95% CIn=1.28--5.12), non-Hodgkin\'s lymphoma (AHR=2.03, 95% CIn=1.22--3.39), head and neck cancer (AHR=2.43, 95% CIn=1.67--3.54), lip cancer (AHR=9.85, 95% CIn=1.25--77.9), oral cavity cancer (AHR=3.03, 95% CIn=1.82--5.04), pancreatic cancer (AHR=2.39, 95% CIn=1.09--5.24), skin cancer (AHR=2.35, 95% CIn=1.07--5.17), and thyroid cancer (AHR=1.45, 95% CIn=1.00--2.10).

###### Incidences and hazard ratios of primary cancers between individuals with and without candida infection

  Site of cancer               Candida infection   Crude HR (95 % CIn)   Adjusted HR (95 % CIn)                                   
  ---------------------------- ------------------- --------------------- ------------------------ ------ ------------------------ ------------------------
  All cancers                  919                 3.73                  1169                     3.93   1.17(1.05, 1.30)\*\*     1.19(1.09, 1.30)\*\*\*
  Hematologic malignancy       41                  0.17                  93                       0.31   2.29(1.50, 3.49)\*\*\*   2.20(1.52, 3.18)\*\*\*
   Hodgkin\'s disease          2                   0.01                  3                        0.01   1.00(0.14, 7.10)         1.41(0.23, 8.48)
   Lymphoblastic leukemia      2                   0.01                  7                        0.02   3.50(0.73, 16.8)         3.57(0.74, 17.2)
   Myeloid leukemia            11                  0.04                  30                       0.10   2.88(1.29, 6.43)\*       2.56(1.28, 5.12)\*\*
   Non-Hodgkin\'s lymphoma     22                  0.09                  46                       0.15   2.27(1.24, 4.16)\*\*     2.03(1.22, 3.39)\*\*
  Head and neck cancer         39                  0.16                  94                       0.32   2.40(1.57, 3.67)\*\*\*   2.43(1.67, 3.54)\*\*\*
   Lip                         1                   0.00                  9                        0.03   7.00(0/86, 56.9)         9.85(1.25, 77.9)\*
   Oral cavity                 20                  0.08                  59                       0.20   2.94(1.67, 5.18)\*\*\*   3.03(1.82, 5.04)\*\*\*
   Oropharynx                  5                   0.02                  5                        0.02   3.00(0.31, 28.8)         0.97(0.28, 3.39)
   Nasopharynx                 12                  0.05                  16                       0.05   1.00(0.43, 2.31)         1.23(0.58, 2.61)
   Hypopharynx                 1                   0.00                  3                        0.01   2.00(0.18, 22.1)         3.29(0.34, 31.7)
  Esophagus                    6                   0.02                  12                       0.04   1.33(0.46, 3.84)         2.14(0.80, 5.70)
  Stomach                      34                  0.14                  33                       0.11   0.88(0.50, 1.56)         0.99(0.61, 1.61)
  Colon, rectum                112                 0.46                  124                      0.42   0.98(0.71, 1.33)         1.08(0.84, 1.40)
  Liver                        89                  0.36                  90                       0.30   1.06(0.72, 1.58)         0.99(0.73, 1.33)
  Pancreas                     9                   0.04                  21                       0.07   1.86(0.74, 4.65)         2.39(1.09, 5.24)\*
  Larynx                       3                   0.01                  2                        0.01   1.00(0.14, 7.10)         0.77(0.13, 4.67)
  Lung                         92                  0.37                  114                      0.38   1.23(0.87, 1.74)         1.21(0.92, 1.60)
  Malignant melanoma of skin   3                   0.01                  4                        0.01   1.50(0.25, 8.98)         1.10(0.24,5.01)
  Skin                         9                   0.04                  21                       0.07   1.43(0.54, 3.75)         2.35(1.07, 5.17)\*
  Breast cancer                225                 0.91                  260                      0.87   0.95(0.76, 1.18)         0.98(0.81, 1.17)
  Kaposi\'s sarcoma            0                   0.00                  2                        0.01   \-                       \-
  Immune-related cancers       155                 0.63                  179                      0.60   1.20(0.91, 1.58)         1.11(0.89, 1.38)
  Cervix                       41                  0.17                  37                       0.12   0.80(0.47, 1.37)         0.81(0.52, 1.27)
  Endometrium                  31                  0.13                  27                       0.09   0.73(0.38, 1.39)         0.72(0.43, 1.21)
  Ovary                        28                  0.11                  33                       0.11   0.78(0.42, 1.45)         0.98(0.59, 1.62)
  Prostate                     27                  0.11                  15                       0.05   1.00(0.43, 2.31)         0.70(0.37, 1.32)
  Bladder, kidney              40                  0.16                  47                       0.16   1.09(0.62, 1.92)         1.21(0.79, 1.85)
  Brain                        10                  0.04                  9                        0.03   2.25(0.69, 7.31)         0.79(0.32, 1.95)
  Thyroid                      44                  0.18                  81                       0.27   1.47(0.95, 2.27)         1.45(1.00, 2.10)\*
  Others                       36                  0.15                  50                       0.17   1.13(0.65, 1.98)         1.30(0.85, 2.01)

Rate^\#^, incidence rate, per 1,000 person-years; Crude HR, relative hazard ratio; Adjusted HR^†^: multivariable analysis including age, sex, monthly-income, urbanization level, occupation, and comorbidity of chronic obstructive pulmonary disease, connective tissue disease, chronic renal failure, chronic liver failure, inflammatory bowel disease, diabetes, hypertension, hyperlipidemia, HIV infection, coronary artery disease, and drug dependence.

\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.

Men with CI exhibited a significantly higher risk of all cancers, hematologic malignancy, head and neck cancer, and oral cavity cancer compared with men without CI (Table [3](#T3){ref-type="table"}). Women with CI had 1.62- and 1.83-fold significantly higher risks of hematologic malignancy and non-Hodgkin\'s lymphoma, respectively, compared with women without CI.

###### Cox model with hazard ratios and 95% confidence intervals of sub-division cancer associated with candida infection stratified by sex

  Variable (ICD-9-CM)        Male with candida infection   Adjusted HR^†^ (95% CIn)   Female with candida infection   Adjusted HR^†^ (95% CIn)                                                      
  -------------------------- ----------------------------- -------------------------- ------------------------------- -------------------------- ------------------------ ----- ------ ----- ------ --------------------
  All cancers                193                           10.1                       284                             16.2                       1.66(1.38, 2.00)\*\*\*   726   3.20   885   3.16   1.07(0.97, 1.18)
  Hematologic malignancy     5                             0.26                       30                              1.71                       6.35(2.46, 16.4)\*\*\*   36    0.16   63    0.22   1.62(1.08, 2.45)\*
   Myeloid leukemia          0                             0.00                       13                              0.74                       \-                       11    0.05   17    0.06   1.30(0.61, 2.80)
   Non-Hodgkin\'s lymphoma   4                             0.21                       11                              0.63                       2.98(0.95, 9.37)         18    0.08   35    0.12   1.83(1.03, 3.25)\*
  Head and neck cancer       16                            0.83                       70                              3.99                       4.73(2.75, 8.15)\*\*\*   23    0.10   24    0.09   0.93(0.52, 1.65)
   Lip                       0                             0.00                       8                               0.46                       \-                       1     0.00   1     0.00   0.12(0.01, 20.1)
   Oral cavity               10                            0.52                       52                              2.96                       5.60(2.84, 11.0)\*\*\*   10    0.04   7     0.02   0.61(0.23, 1.61)
  Pancreas                   27                            1.41                       15                              0.85                       0.70(0.37, 1.32)         0     0.00   0     0.00   \-
  Skin                       2                             0.10                       8                               0.46                       4.60(0.97, 21.7)         7     0.03   13    0.05   1.78(0.70, 4.51)
  Thyroid                    1                             0.05                       3                               0.17                       3.10(0.32, 30.0)         43    0.19   78    0.28   1.40(0.96, 2.04)

Rate^\#^, incidence rate, per 1,000 person-years; Adjusted HR^†^: multivariable analysis including age, sex, monthly-income, urbanization level, occupation, and comorbidity of chronic obstructive pulmonary disease, connective tissue disease, chronic renal failure, chronic liver failure, inflammatory bowel disease, diabetes, hypertension, hyperlipidemia, HIV infection, coronary artery disease, and drug dependence.

\*p\<0.05, \*\*\*p\<0.001.

Among the patients aged ≤49 years, those with CI were at a higher risk of hematologic malignancy and oral cavity cancer compared with those without CI (Table [4](#T4){ref-type="table"}). Among the patients aged ≥50 years, those with CI were at a higher risk of all cancers, hematologic malignancy, myeloid leukemia, non-Hodgkin\'s lymphoma, head and neck cancer, lip cancer, oral cavity cancer, and thyroid cancer compared with those without CI.

###### Cox model with hazard ratios and 95% confidence intervals of sub-division cancer associated with candida infection stratified by age

  Variable (ICD-9-CM)       Age≤49 years   Age ≥50 years                       
  ------------------------- -------------- -------------------- -------------- ------------------------
  All cancers               1(Reference)   0.96(0.85, 1.09)     1(Reference)   1.27(1.12, 1.43)\*\*\*
  Hematologic malignancy    1(Reference)   1.78(1.04, 3.04)\*   1(Reference)   2.41(1.45, 4.02)\*\*\*
   Myeloid leukemia         1(Reference)   2.10(0.87, 5.08)     1(Reference)   3.24(1.05, 9.96)\*
   Non-Hodgkin\'slymphoma   1(Reference)   1.61(0.72, 3.61)     1(Reference)   2.12(1.09, 4.09)\*
  Head and neck cancer      1(Reference)   1.58(0.93, 2.68)     1(Reference)   3.54(2.06, 6.10)\*\*\*
   Lip                      1(Reference)   \-                   1(Reference)   9.65(1.22, 76.3)\*
   Oral cavity              1(Reference)   2.12(1.04, 4.34)\*   1(Reference)   4.20(2.01, 8.75)\*\*\*
  Pancreas                  1(Reference)   \-                   1(Reference)   0.72(0.38, 1.37)
  Skin                      1(Reference)   1.32(0.22, 8.13)     1(Reference)   2.35(0.97, 5.65)
  Thyroid                   1(Reference)   1.25(0.84, 1.87)     1(Reference)   2.93(1.07, 8.03)\*

Adjusted HR^†^: multivariable analysis including age, sex, monthly-income, urbanization level, occupation, and comorbidity of chronic obstructive pulmonary disease, connective tissue disease, chronic renal failure, chronic liver failure, inflammatory bowel disease, diabetes, hypertension, hyperlipidemia, HIV infection, coronary artery disease, and drug dependence.

\*p\<0.05, \*\*\*p\<0.001.

Furthermore, the AHRs for cancer types were stratified according to follow-up duration (Table [5](#T5){ref-type="table"}). Among the patients with a follow-up duration of ≤1 year, those with CI exhibited a significantly higher risk of all cancers and non-Hodgkin\'s lymphoma compared with those without CI. Among the patients with 1 year \< follow-up duration ≤5 years, those with CI had a 1.47-fold higher risk of all cancers, 2.64-fold higher risk of head and neck cancer, 2.35-fold higher risk of oral cavity cancer, and 4.05-fold significantly higher risk of thyroid cancer compared with those without CI. However, among the patients with a follow-up duration of \>5 years, patients with CI had a 6.34-fold higher risk of skin cancer compared with those without CI.

###### Cox model with hazard ratios and 95% confidence intervals of sub-division cancer associated with candida infection stratified by follow-up time

  Variable(ICD-9-CM)         Follow-up time ≤1 year   1 year \<Follow-up time ≤5 years   Follow-up time \>5 years                                           
  -------------------------- ------------------------ ---------------------------------- -------------------------- ------------------------ -------------- --------------------
  All cancers                1(Reference)             1.31(1.03, 1.67)\*                 1(Reference)               1.47(1.27, 1.69)\*\*\*   1(Reference)   1.12(0.99, 1.28)
  Hematologic malignancy     1(Reference)             7.15(0.97, 1.00)                   1(Reference)               1.68(0.89, 3.15)         1(Reference)   1.34(073, 2.46)
   Myeloid leukemia          1(Reference)             \-                                 1(Reference)               2.17(0.69, 6.89)         1(Reference)   1.53(0.56, 4.20)
   Non-Hodgkin\'s lymphoma   1(Reference)             6.39(1.84, 22.1)\*\*               1(Reference)               1.69(0.66, 4.30)         1(Reference)   1.05(0.46, 2.38)
  Head and neck cancer       1(Reference)             2.44(0.89, 6.69)                   1(Reference)               2.64(1.54, 4.52)\*\*\*   1(Reference)   1.16(0.56, 2.38)
   Lip                       1(Reference)             \-                                 1(Reference)               4.93(0.54, 45.0)         1(Reference)   \-
   Oral cavity               1(Reference)             2.88(0.64, 13.0)                   1(Reference)               2.35(1.15, 4.82)\*       1(Reference)   1.68(0.61, 4.61)
  Pancreas                   1(Reference)             0.07(0.00, 1.51)                   1(Reference)               1.13(0.45, 2.82)         1(Reference)   0.39(0.13, 1.19)
  Skin                       1(Reference)             0.34(0.02, 6.43)                   1(Reference)               2.19(0.62, 7.78)         1(Reference)   6.34(1.43, 28.2)\*
  Thyroid                    1(Reference)             0.82(0.29, 2.31)                   1(Reference)               4.05(2.01, 8.18)\*\*\*   1(Reference)   1.21(0.73, 2.00)

Adjusted HR^†^: multivariable analysis including age, sex, monthly-income, urbanization level, occupation, and comorbidity of chronic obstructive pulmonary disease, connective tissue disease, chronic renal failure, chronic liver failure, inflammatory bowel disease, diabetes, hypertension, hyperlipidemia, HIV infection, coronary artery disease, and drug dependence.

\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.

Compared with the non-CI cohort, patients with candidiasis of the mouth exhibited a higher risk of all cancers (AHR = 2.24, 95% CIn = 1.91--2.63), hematologic malignancy(AHR = 9.54, 95% CIn = 5.79--15.7), myeloid leukemia (AHR = 14.0, 95% CIn = 5.71--34.3), non-Hodgkin\'s lymphoma (AHR = 8.92, 95% CIn = 4.49--17.7), head and neck cancer (AHR = 12.9, 95% CIn = 8.40--19.7), oral cavity cancer (AHR = 13.9, 95% CIn = 7.97--24.4), skin cancer (AHR = 4.99, 95% CIn = 1.72--14.5), and thyroid cancer (AHR = 2.75, 95% CIn = 1.22--6.20) (Table [6](#T6){ref-type="table"}).

###### Incidence rates and hazard ratios of primary cancers in subgroups of candida infection

  Variables                 N       Event   Rate^†^   Crude HR(95 % CIn)       Adjusted HR^†^(95 % CIn)
  ------------------------- ------- ------- --------- ------------------------ --------------------------
  All cancers                                                                  
   Control cohort           34829   919     3.73      1(Reference)             1(Reference)
   Candidiasis of mouth     2156    195     13.5      3.61(3.10, 4.22)\*\*\*   2.24(1.91, 2.63)\*\*\*
   Vulva and vagina         28072   669     2.61      0.67(0.61, 0.75)\*\*\*   1.00(0.90, 1.11)
   Other urogenital sites   544     24      9.20      2.51(1.67, 3.76)\*\*\*   1.07(0.71, 1.61)
  Hematologic malignancy                                                       
   Control cohort           34829   41      0.17      1(Reference)             1(Reference)
   Candidiasis of mouth     2156    29      2.01      12.0(7.44, 19.3)\*\*\*   9.54(5.79, 15.7)\*\*\*
   Vulva and vagina         28072   23      0.09      0.54(0.32, 0.90)\*       0.68(0.40, 1.15)
   Other urogenital sites   544     3       1.15      6.62(2.05, 21.4)\*\*     3.41(1.03, 11.3)\*
  Myeloid leukemia                                                             
   Control cohort           34829   11      0.04      1(Reference)             1(Reference)
   Candidiasis of mouth     2156    10      0.69      15.4(6.54, 36.3)\*\*\*   14.0(5.71, 34.3)\*\*\*
   Vulva and vagina         28072   6       0.02      0.50(0.18, 1.35)         0.53(0.19, 1.45)
   Other urogenital sites   544     0       0.00      \-                       \-
  Non-Hodgkin\'s lymphoma                                                      
   Control cohort           34829   22      0.09      1(Reference)             1(Reference)
   Candidiasis of mouth     2156    15      1.04      11.5(5.97, 22.2)\*\*\*   8.92(4.49, 17.7)\*\*\*
   Vulva and vagina         28072   14      0.05      0.61(0.31, 1.19)         0.89(0.44, 1.78)
   Other urogenital sites   544     1       0.38      4.03(0.54, 29.9)         1.53(0.20, 11.6)
  Head and neck cancer                                                         
   Control cohort           34829   39      0.16      1(Reference)             1(Reference)
   Candidiasis of mouth     2156    66      4.57      28.6(19.3, 42.5)\*\*\*   12.9(8.40, 19.7)\*\*\*
   Vulva and vagina         28072   12      0.05      0.32(0.17, 0.60)\*\*\*   0.54(0.27,1.06)
   Other urogenital sites   544     0       0.00      \-                       \-
  Lip cancer                                                                   
   Control cohort           34829   1       0.00      1(Reference)             1(Reference)
   Candidiasis of mouth     2156    8       0.55      \-                       \-
   Vulva and vagina         28072   0       0.00      \-                       \-
   Other urogenital sites   544     0       0.00      \-                       \-
  Oral cavity                                                                  
   Control cohort           34829   20      0.08      1(Reference)             1(Reference)
   Candidiasis of mouth     2156    45      3.11      37.9(22.4, 64.2)\*\*\*   13.9(7.97, 24.4)\*\*\*
   Vulva and vagina         28072   4       0.02      0.21(0.07, 0.61)\*\*     0.45(0.15, 1.40)
   Other urogenital sites   544     0       0.00      \-                       \-
  Pancreas                                                                     
   Control cohort           34829   9       0.04      1(Reference)             1(Reference)
   Candidiasis of mouth     2156    1       0.07      1.89(0.24, 14.9)         1.04(0.13, 8.35)
   Vulva and vagina         28072   12      0.05      1.25(0.52, 2.98)         2.51(0.95, 6.63)
   Other urogenital sites   544     0       0.00      \-                       \-
  Skin                                                                         
   Control cohort           34829   9       0.04      1(Reference)             1(Reference)
   Candidiasis of mouth     2156    6       0.42      11.3(4.03, 31.8)\*\*\*   4.99(1.72, 14.5)\*\*
   Vulva and vagina         28072   7       0.03      0.70(0.26, 1.90)         1.55(0.53, 4.57)
   Other urogenital sites   544     1       0.38      10.7(1.35, 84.4)\*       2.53(0.31, 20.7)
  Thyroid                                                                      
   Control cohort           34829   44      0.18      1(Reference)             1(Reference)
   Candidiasis of mouth     2156    7       0.48      2.71(1.22, 6.03)\*       2.75(1.22, 6.20)\*
   Vulva and vagina         28072   66      0.26      1.35(0.92, 1.99)         1.30(0.88, 1.92)
   Other urogenital sites   544     0       0.00      \-                       \-

Rate^\#^, incidence rate, per 1,000 person-years; Crude HR, relative hazard ratio. Adjusted HR^†^, multivariable analysis including age, sex, monthly-income, urbanization level, occupation, and comorbidity of chronic obstructive pulmonary disease, connective tissue disease, chronic renal failure, chronic liver failure, inflammatory bowel disease, diabetes, hypertension, hyperlipidemia, HIV infection, coronary artery disease, and drug dependence.

\*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001.

DISCUSSION {#s3}
==========

The main finding of this study is that patients with CI had significantly higher risks of overall cancer as well as hematologic malignancy, head and neck cancer, pancreatic cancer, skin cancer, and thyroid cancer. According to stratified analyses, significantly higher risks were more likely observed in men, participants aged ≥50 years, and at a follow-up time between 1 and 5 years.

Several plausible mechanisms support the argument that *Candida* might induce cancer \[[@R17]\]. First, *Candida* can produce compounds such as nitrosamines, which are identified carcinogens that play a role in oral cancer initiation \[[@R18], [@R19]\]. Second, a previous study suggested that *C. albicans* promotes cancer through a proinflammatory response, mediated by an increase in cytokine production and adhesion-molecule expression \[[@R17]\]. It is increasingly clear that the tumor microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process \[[@R20], [@R21]\]. Other hypotheses, such as the induction of Th17 response and molecular mimicry, have also been proposed to explain the mechanism by which *C. albicans* might promote cancer progression \[[@R17], [@R22], [@R23]\].

Nørgaard et al. used nationwide medical registries in Denmark to investigate the association between CI and cancer risk, observing an increase in both short- and long-term risks in all cancers; immune-related cancers; and cancers of several individual sites, such as the oral cavity, oropharynx, esophagus, larynx, and lung \[[@R16]\]. In our analyses, we adjusted for some chronic diseases that may be associated with immunosuppression. The results revealed significantly higher cancer risks among patients with CI for all cancers, hematologic malignancy, oral cavity cancer, lip cancer, pancreatic cancer, skin cancer, and thyroid cancer. Increased oral and lip cancer risks were expected on the basis of previous findings \[[@R13], [@R15]--[@R17]\]. CI and certain types of cancer are well-documented as being related to immunocompromised status \[[@R6], [@R12]\]. Immune-related cancers include liver, cervical, and anal cancers; malignant melanoma; non-Hodgkin\'s lymphoma; and Kaposi\'s sarcoma \[[@R12], [@R16]\]. Nørgaard et al. reported that patients with CI were at higher risks of all immune-related cancers pooled together and certain individual immune-related cancers, including non-Hodgkin\'s lymphoma and Kaposi\'s sarcoma \[[@R16]\]. By contrast, our analysis revealed that patients with CI had a significantly increased risk only for non-Hodgkin\'s lymphoma, and not for other immune-related cancers, either at individual sites or pooled together. Kaposi\'s sarcoma is relatively uncommon in Taiwan; we had only two cases in the CI cohort and no cases in the non-CI cohort. For other cancer sites, our results are partially consistent with the findings of Nørgaard et al., and revealed that patients with CI had an increased risk of oral cancer, lip cancer, and all head and neck cancers pooled together, in comparison with non-CI participants.

Recently, Zhu et al. reported that fungal infection promoted esophageal squamous cell carcinoma development in mice and that fungal infection was tightly associated with human esophageal squamous cell carcinoma \[[@R24]\]. Our data did not show a significant difference for the risk of esophageal cancer, and National Health Insurance Research Database (NHIRD) did not provide the pathological information for us to clarify if there is an increased risk of esophageal cancer if we separate squamous cell carcinoma from all the pathological types of esophageal cancer. By contrast, we unexpectedly detected significantly increased risks for pancreatic, skin, and thyroid cancers in patients with CI. We do not have sufficient evidence to explain this phenomenon; however, it may be partially related to the surveillance bias, particularly for skin and thyroid cancer. Patients with CI are assumed to visit dermatologists and head and neck specialists more frequently because of their infection sites (skin and oral cavity); consequently, the detection of more skin and thyroid cancers can be expected. The stratified analyses revealed different patterns in different categories. Although the majority of our patients with CI were women, male patients with CI were more likely to exhibit an increased risk of all cancers and individual cancers, particularly head and neck cancer and oral cavity cancer. Men tend to have poorer oral hygiene than women, which may increase the risk of both CI and head and neck cancers in men \[[@R25], [@R26]\]. Patients with CI aged 50 years or older are likely to exhibit more significant findings than younger patients with CI. Cancer is more common in elderly people, which may partially explain this finding. For the follow-up time, patients with CI with a follow-up time between 1 and 5 years exhibited a significantly higher risk of overall and individual cancers. However, a tendency of increased long-term risk of overall cancer was observed among patients with CI (95% CIn: 0.99--1.28).

The female: male ratio for our patients with CI was approximately 10:1, and the majority of our CI sites were the vulva and vagina. Therefore, we conducted a further analysis and specified candidiasis of the mouth, vulva and vagina, and other urogenital sites to assess whether cancer risk was specific to CI sites. Patients with candidiasis of the mouth exhibited a significantly increased risk of all cancers and individual cancers, except lip and pancreatic cancers (Table [6](#T6){ref-type="table"}). By contrast, candidiasis of the vulva and vagina and other urogenital sites exhibited a considerably weaker association with overall or individual cancer risk.

The main strength of this study is the use of a nationwide database and longitudinal and comprehensive follow-up, which increased the generalizability of the findings. Furthermore, all National Health Insurance (NHI) claims are scrutinized by medical reimbursement specialists and peer reviewed to prevent errors and overutilization of medical resources; therefore, the diagnoses of CI and cancer are strongly validated. However, a few limitations must be acknowledged before our findings are interpreted. First, the NHI database lacks information on the life styles and health behaviors of patients, which prevented us from adjusting for potential confounding factors such as smoking and alcohol consumption in our analyses. Smoking and alcohol consumption are important predisposing factors for both CI \[[@R27], [@R28]\] and certain types of cancer \[[@R29]\]. Second, lack of individual microbiology data for CI and pathological data for tumor histology and staging in the NHIRD, so we could not identify the Candida species in patients with CI, which prevented us from conducting more sophisticated analyses to specify the role of C. albicans in the occurrence of cancer. We would not able to evaluate the relationship between CI infection and tumor histology/severity either. Third, possibly under-diagnosed or underestimated asymptomatic CI could exist, which might impact our results. Finally, surveillance bias, as mentioned earlier, could have distorted our results; however, this is less likely because more significant findings were detected during a follow-up time between 1 and 5 years, instead of less than 1 year (Table [5](#T5){ref-type="table"}).

In conclusion, in this study, patients with CI exhibited higher risks of overall cancer as well as head and neck cancer, oral cancer, lip cancer, and non-Hodgkin\'s lymphoma, which is compatible with earlier reports. However, an unexpectedly high number of pancreatic, skin, and thyroid cancer cases were detected, and no confirmatory mechanisms could be identified to explain this phenomenon. Additional large-scale and comprehensive studies are warranted to support our findings.

MATERIALS AND METHODS {#s4}
=====================

Data source {#s4_1}
-----------

Approximately 99% of Taiwan\'s 23.74 million residents are covered by the NHI program, which was implemented in March 1995 \[[@R30]\]. The data in this retrospective cohort study were retrieved from the Taiwan Longitudinal Health Insurance Database2000 (LHID 2000). The data of one million people randomly selected from the medical claims records of the NHI 2000 Registry of Beneficiary enrollees were analyzed. The LHID2000 has been successfully used innumerous studies \[[@R31], [@R32]\].

Ethics statement {#s4_2}
----------------

The NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH104-REC2-115-CR1). The IRB also specifically waived the consent requirement.

Sampled participants {#s4_3}
--------------------

Figure [1](#F1){ref-type="fig"} shows the selection process of the participants in the 2 study cohorts. For the CI cohort, we selected patients aged ≥20 years and newly diagnosed as having CI \[International Classification of Diseases (ICD)-9-CM code 112\], including candidiasis of the mouth (ICD-9-CM code 112.0), vulva and vagina (ICD-9-CM code 112.1), other urogenital sites, and other sites, from January 1, 2000 to December 31, 2012. The CI diagnosis date was defined as the index date. Participants without CI were selected from the LHID2000 as the non-CI cohort. Patients in both the CI and non-CI cohorts who had previously received a diagnosis of cancer (ICD-9-CM code 140--208) were excluded. For each patient with CI, one non-CI control was frequency matched by age, sex, monthly income, urbanization level, occupation, year of index date, and comorbidity (chronic obstructive pulmonary disease, connective tissue disease, chronic renal failure, chronic liver failure, inflammatory bowel disease, diabetes, hypertension, hyperlipidemia, HIV infection, coronary artery disease, and drug dependence).

![The selection process of the participants in the 2 study cohorts](oncotarget-08-63562-g001){#F1}

Outcome measurement {#s4_4}
-------------------

We obtained data on patients who were diagnosed with cancer (ICD-9-CM codes 140--195, and 200--208) during 2000--2013 from the Registry for Catastrophic Illness Patient Database (RCIPD). Cancer registration in the RCIPD requires histological or pathological confirmation or a physician\'s confirmation. All participants were followed up from the index date until the date of cancer diagnosis, death, withdrawal from the NHI program, or the end of 2013.

Statistical analysis {#s4_5}
--------------------

We first compared the distribution differences of sociodemographic variables and baseline comorbidities between the CI and non-CI cohorts by using the chi-square test for categorical variables and *t* test for continuous variables. The follow-up person-years were calculated to assess incidence density rates until the cancer was either identified or censored. Univariable and multivariable Cox proportional hazards models were used to estimate the hazard ratios and 95% CIns of the risk of cancer associated with CI compared with the non-CI cohort. The multivariable models were simultaneously adjusted for age, sex, monthly income, urbanization level, occupation, and comorbidities. Models were also used for estimating the risks of cancer stratified by sex, age group, and follow-up period. Further analysis was performed to assess whether the type of CI had a role in cancer outcomes. All analyses were performed using SAS for Windows (Version 9.4; SAS Institute, Inc., Cary, NC, USA), and the significance level was set at 0.05.
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